Welcome to our dedicated page for Cross Ctry Healthcare SEC filings (Ticker: CCRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When analysts search for Cross Country Healthcare insider trading Form 4 transactions or wonder how travel-nurse margins shift quarter to quarter, they usually start with the raw SEC documents. Yet combing through a 250-page annual report or multiple 8-K updates is time-consuming. This page gathers every Cross Country Healthcare SEC filing explained simply so you can focus on signals like fill-rate trends, bill-rate inflation, and MSP contract renewals—not on document hunting.
Use Stock Titan’s AI-powered summaries to see the heart of each report in minutes. Real-time alerts flag new Cross Country Healthcare Form 4 insider transactions, while side-by-side comparisons reveal how quarterly labor costs evolve inside each Cross Country Healthcare quarterly earnings report 10-Q filing. Want the big picture? Our tool highlights cash-flow swings, clinician shortage commentary, and risk disclosures inside the Cross Country Healthcare annual report 10-K simplified. We also decode proxy filings so you can quickly answer questions about Cross Country Healthcare proxy statement executive compensation.
Investors frequently track:
- 8-K material events explained—client wins, MSP renewals, or leadership changes that move staffing demand.
- Cross Country Healthcare Form 4 insider transactions real-time—monitor executive stock moves before earnings.
- Cross Country Healthcare earnings report filing analysis—spot quarter-over-quarter gross-margin shifts.
Cross Country Healthcare (CCRN) filed its Q3 2025 10‑Q, reporting revenue of $250,052 thousand and a net loss of $4,774 thousand, or $0.15 per diluted share. For the nine months, revenue was $817,532 thousand with a net loss of $11,923 thousand.
Results reflected softer volumes and several non-core charges. The quarter included $4,147 thousand of Aya Merger-related fees, $1,530 thousand of restructuring costs, and $1,102 thousand of legal and other losses. Operating loss was $5,973 thousand. Nurse and Allied Staffing generated $201,950 thousand of revenue; Physician Staffing contributed $48,102 thousand.
Liquidity remained solid: cash and cash equivalents were $99,132 thousand with no debt outstanding. The asset‑based revolver had $121.4 million of borrowing base availability, or $103.0 million net of $18.4 million in letters of credit. Operating cash flow was $30,012 thousand year‑to‑date. The pending Aya Merger remains subject to FTC review under the HSR Act; the HSR waiting period extends during the government shutdown, and the parties are discussing an end‑date extension.
Cross Country Healthcare (CCRN) set its 2025 Annual Meeting for December 9, 2025 at 12:00 p.m. ET, to be held virtually at www.virtualshareholdermeeting.com/CCRN2025. Stockholders of record as of October 14, 2025 may vote.
The agenda includes three items: elect seven director nominees for one-year terms; ratify Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025; and approve, on a non-binding advisory basis, 2024 executive compensation.
The company notes its proposed merger with Aya Healthcare, Inc. is expected to close in the fourth quarter of 2025; the Annual Meeting will not be held if the merger closes before December 9.
Governance highlights include a seven-member Board with a Lead Independent Director and fully independent Audit, Compensation, and Governance & Nominating Committees. 2024 results cited include revenue above $1.3 billion, Adjusted EBITDA of $49.1 million (3.7% margin), Adjusted EPS of $0.46, strong cash flow of $120.1 million, repurchases of 2.4 million shares for $36.8 million, and no outstanding long-term debt.
On September 25, 2025 Cross Country Healthcare, Inc. announced its Board set the 2025 virtual-only Annual Meeting for December 9, 2025, which is more than 30 days after last year’s meeting. The meeting will only occur if the pending merger with Aya Healthcare, Inc. (the Aya Merger) is not completed beforehand; the company continues to expect the Aya Merger to close in the fourth quarter of 2025. If the merger is completed first, Cross Country will become a wholly owned subsidiary of Aya and the Annual Meeting will not be held. The company set a deadline of October 10, 2025 for stockholder proposals, nominations and Rule 14a-19 universal proxy notices, and said the proxy statement will be made available by or prior to October 30, 2025.
Cross Country Healthcare disclosed that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly hold 1,887,473.57 shares of its common stock, equal to 5.8% of the class. The filing identifies GS Group as a parent holding company and Goldman Sachs & Co. LLC as a broker-dealer and registered investment adviser that may own the securities on the parent’s behalf. The reporting parties certify the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing includes a joint filing agreement and an exhibit identifying the subsidiary relationship.
Cross Country Healthcare (CCRN) Q2 2025 10-Q highlights:
- Revenue fell 19.3 % YoY to $274.1 million; six-month revenue declined 21.1 % to $567.5 million as travel-nurse volumes and bill rates continued to normalize.
- Loss from operations narrowed to $5.9 million (vs. $19.2 million loss LY). Net loss improved to $6.7 million or -$0.20 EPS (LY: -$0.47).
- Gross margin slipped 30 bp YoY to 20.4 % as lower pricing offset cost controls; SG&A down 17 % to $50.1 million.
- Operating cash flow was positive at $9.9 million YTD but sharply below $88.4 million LY, reflecting lower earnings and working-capital unwind.
- Balance sheet remains debt-free; cash & equivalents stable at $81.2 million. Equity totals $412.2 million (book value ≈ $12.7/share).
- Aya Healthcare take-private deal progressing: FTC issued a Second Request on 20 Feb 2025; close expected 4Q 2025. CCRN incurred $6.0 million Q2 and $8.0 million YTD in merger-related costs.
- Segments: Nurse & Allied supplied 82 % of revenue, down 23 %. Physician Staffing rose 3 % YoY.
- No share repurchases in Q2; $40.5 million remains authorized.
Key takeaways: While demand headwinds continue to pressure top line, CCRN preserved liquidity, maintained a debt-free balance sheet, and reduced losses. Future value for shareholders now hinges on successful completion of the Aya merger and potential go-private premium.
FAQ
What is the current stock price of Cross Ctry Healthcare (CCRN)?
What is the market cap of Cross Ctry Healthcare (CCRN)?
